A Randomized, Double-Blind, Placebo-Controlled, Escalating Dose, Pilot Study to Evaluate the Safety, Tolerability and Biologic Activity of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Pyridoxamine (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Sponsors BioStratum
Most Recent Events
- 26 Sep 2014 New trial record